Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 26, 2017 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Presenting at the 23rd Annual International Partnering Conference BIO-EUROPE®

Berlin, 6-8 November 2017 NANTES, France, Oct. 26, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173) (Mnémo:OSE), today announces it will be featured as a presenting company...
October 19, 2017 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Publishes New Data on FR104, CD28-Antagonist Immunotherapy

FR104 shows immune tolerance superiority over CTLA4-Ig in humanized skin transplant model FR104 efficacious in graft-versus-host reaction in bone marrow transplant model NANTES, France, Oct. 19,...
October 02, 2017 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Presents New Data Strengthening the Rationale of Myeloid Checkpoint Inhibitor OSE-172 as an Immune Cancer Treatment

Company Intends to Enter Clinic with OSE-172 in Oncology by End of 2018 Data presented at 15th Annual “Discovery on Target” Conference NANTES, France, Oct. 02, 2017 (GLOBE NEWSWIRE) -- OSE...
September 28, 2017 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Signs a License Option Agreement with Inserm to Develop a New Cancer Immunotherapy Targeting Myeloid Cells

NANTES, France, Sept. 28, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN:FR0012127173) (Mnémo:OSE) today announces that the company has entered into an agreement with Inserm Transfert, on...
September 26, 2017 02:00 ET | Source: OSE Immunotherapeutics; Selexis SA

Selexis SA and OSE Immunotherapeutics Expand Strategic Alliance to Further Advance OSE’s OSE-172 and OSE-703 Cancer Immunotherapy Programs

Second and Third Commercial License Agreements Between the Partners Underscore the Advantages of Selexis’ SUREtechnology Platform™, Aids OSE Immunotherapeutics Candidates’ Advancement into Clinic ...
August 31, 2017 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Announces Presentation at The 19th Annual Rodman & Renshaw Global Investment Conference In New York City, September 10-12, 2017

NANTES, France, Aug. 31, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN:FR0012127173) (Mnémo:OSE), today announced it will be featured as a presenting company at the 19th Annual Rodman...
July 19, 2017 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Receives €9.2 million Grant from Bpifrance “Invest in the Future Program” for Development of New Immune Checkpoint Inhibitor OSE-172 (Effi-DEM)

NANTES, France, July 19, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN:FR0012127173) (Mnémo:OSE) announced today that the Company will receive a €9.2 million grant from the “Projets de...
June 23, 2017 15:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Announces Temporary Pause of Patient Accrual While Continuing Treatment for Patients Already Enrolled In Phase 3 Clinical Trial of Tedopi® in Advanced Lung Cancer

NANTES, France, June 23, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN:FR0012127173) (Mnémo:OSE) today announced that following the recommendation by IDMC (independent experts) on the...
June 21, 2017 12:30 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Receives Payment of €2.6 Million from Bpifrance After Completion of a New Key Milestone for its Product OSE-127

NANTES, France, June 21, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN:FR0012127173) (Mnémo:OSE) announces today that the Company has received €2.597 million from Bpifrance following the...
June 15, 2017 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Presents Positive Preclinical Results and Human Ex Vivo Data for OSE-127 (Effi-7) to Support Next Clinical Applications in Inflammatory Bowel Diseases at the Federation of Clinical Immunology Societies (FOCIS) Conference

OSE-127 Blocks Pathological Homing of Human T Lymphocytes to Inflamed ColonEx vivo, OSE-127 Reduces Production of Gamma Interferon by Human Proinflammatory Bowel T lymphocytes in Patients’ Biopsies ...

keyboard_arrow_left Previous Page